↑ 疾患リストへ ← 戻る

 225. 先天性腎性尿崩症 [臨床試験数:11,薬物数:35(DrugBank:15),標的遺伝子数:30,標的パスウェイ数:61] 

Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs03118036912/04/201810 September 2019Tolvaptan for nephrogenic diabetes insipidusExploratory study of tolvaptan use for nephrogenic diabetes insipidus caused by mutation in vasopressin type 2 receptor - Tolvaptan use for NDI by V2R mutationNephrogenic diabetes insipidus
Nephrogenic diabetes insipidus, polyuria;D018500
Starting tolvaptan from 60 mg and dose up to 90mg and 120mg in every 1 or 2 days.Noriko MakitaRecruiting20agenot applicableBoth3Phase 1-2none
2EUCTR2016-001591-30-DK06/11/201723 July 2018Treatment of congenital nephrogenic diabetes insipidus with riociguat or sildenafilTreatment of congenital nephrogenic diabetes insipidus with a guanylate cyclase stimulator, riociguat or a phosphodiesterase type 5 inhibitor, sildenafilNephrogenic diabetes insipidus because of AVP2R-mutation
MedDRA version: 20.0 Level: LLT Classification code 10012626 Term: Diabetes nephrogenic (excludes glycosuria) System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Adempas
Product Name: Adempas
Pharmaceutical Form: Tablet
INN or Proposed INN: RIOCIGUAT
CAS Number: 625115-55-1
Other descriptive name: RIOCIGUAT
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 3-
Trade Name: Viagra
Product Name: Viagra
Pharmaceutical Form: Tablet
INN or Proposed INN: SILDENAFIL
CAS Number: 139755-83-2
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Odense University HospitalAuthorisedFemale: no
Male: yes
2Phase 2Denmark
3NCT02967653July 13, 201716 December 2017Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes InsipidusAtorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled TrialLithium Use, Nephrogenic Diabetes InsipidusDrug: AtorvastatinLady Davis InstituteRecruiting18 Years85 YearsAll60Phase 2Canada
4JPRN-UMIN0000217082016/04/185 November 2019A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. - A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor geneAdministration of Tolvaptan once per day (60mg/day, 90mg/day, 120mg/day), each dose for two days.Department of Nephrology and Endocrinology, The University of Tokyo HospitalRecruiting20years-oldNot applicableMale and Female3Not selectedJapan
5NCT02460354September 201530 July 2018Metformin and Congenital Nephrogenic Diabetes InsipidusUse of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI)Diabetes InsipidusDrug: MetforminEmory UniversityNot recruiting18 YearsN/AMale2Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2012-001809-24-NL31/07/20135 August 2013A diminished concentrating ability of the kidneys due to lithium prescription: how many and whom is affected?Evaluation of urinary concentrating defects in lithium treated patients with a dDAVP test - Nephrogenic diabetes insipidus (NDI) in lithium treated patientslithium-induced urinary concentrating defects (nephrogenic diabetes insipidus)
MedDRA version: 15.0 Level: LLT Classification code 10050501 Term: Lithium toxicity System Organ Class: 10022117 - Injury, poisoning and procedural complications
MedDRA version: 15.0 Level: LLT Classification code 10012600 Term: Diabetes insipidus nephrogenic System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses
Product Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses
Product Code: SUB21605
Pharmaceutical Form: Nasal spray, solution
INN or Proposed INN: desmopressin acetate trihydrate
CAS Number: 62357-86-2
Current Sponsor code: not applicable
Other descriptive name: DESMOPRESSIN ACETATE TRIHYDRATE
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 0.1-
Radboud University Nijmegen Medical CentreAuthorisedFemale: yes
Male: yes
Netherlands
7EUCTR2011-005970-41-NL27/02/201214 January 2013The effect of the drug acetazolamide on excessive urine production due to a diminished concentrating ability of the kidney as a result of the use of lithium in patients with an affective disorder: a pilot studyThe effect of acetazolamide on lithium-induced nephrogenic diabetes insipidus in patients with an affective disorder: a pilot studylithium-induced nephrogenic diabetes insipidus
MedDRA version: 14.1 Level: LLT Classification code 10012600 Term: Diabetes insipidus nephrogenic System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 14.1 Level: LLT Classification code 10050501 Term: Lithium toxicity System Organ Class: 10022117 - Injury, poisoning and procedural complications ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Acetazolamide Sandoz 250
Pharmaceutical Form: Tablet
CAS Number: 59-66-5
Other descriptive name: ACETAZOLAMIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 250-
Radboud University Nijmegen Medical CentreAuthorisedFemale: yes
Male: yes
Netherlands
8EUCTR2006-003360-56-DK28/08/200927 October 2014Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDYFarmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDYKongenit nefrogen diabetes insipidus
MedDRA version: 14.1 Level: PT Classification code 10068304 Term: Congenital nephrogenic diabetes insipidus System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: Confortid
Pharmaceutical Form: Tablet
INN or Proposed INN: INDOMETACIN
CAS Number: 53-86-1
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Trade Name: Losec
Pharmaceutical Form: Tablet
INN or Proposed INN: OMEPRAZOLE MAGNESIUM
CAS Number: 95382335
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Trade Name: Viagra
Pharmaceutical Form: Tablet
CAS Number: 171599-83-0
Other descriptive name: SILDENAFIL CITRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
Trade Name: Miacalcic
Pharmaceutical Form: Nasal spray
CAS Number: 47931-85-1
Other descriptive name: CALCITONIN (SALMON)
Concentration unit: IU international unit(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Nasal spray
Route of administration of the placebo: Intranasal use (Noncurrent)
Trade Name: Spirix
Pharmaceutical Form: Tablet
CAS Number: 52-01-7
Other descriptive name: SPIRONOLACTONE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Trade Name: Esidrix
Product Name: Esidrix
Pharmaceutical Form: Tablet
INN or Proposed INN: HYDROCHLOROTHIAZIDE
CAS Number: 58-93-5
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Dept. of Pediatrics, The Childrens Hospital, DenverNot RecruitingFemale: no
Male: yes
40Denmark
9NCT00478335May 200719 February 2018Pharmacologic Treatment of Congenital Nephrogenic Diabetes InsipidusPharmacologic Treatment of Congenital Nephrogenic Diabetes InsipidusNephrogenic Diabetes InsipidusDrug: sildenafil;Drug: calcitonin;Drug: hydrochlorothiazide/amiloride;Drug: indomethacin;Drug: Placebo for sildenafil;Drug: placebo for calcitoninUniversity of Colorado, DenverUniversity of AarhusNot recruiting5 Years25 YearsMale4N/AUnited States;Denmark
10EUCTR2006-001202-84-NL01/02/200719 March 2012Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDIComparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDILithium-induced Nephrogenic Diabetes Insipidus
MedDRA version: 9.1 Level: LLT Classification code 10012600 Term: Diabetes insipidus nephrogenic
Trade Name: Midamor
Product Name: Amiloride
Pharmaceutical Form: Capsule*
Trade Name: Hydrochloorthiazide
Product Name: hydrochloorthiazide
Pharmaceutical Form: Capsule*
Radboud University Nijmegen Medical CentreAuthorisedFemale: yes
Male: yes
50Netherlands
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00004360September 199519 February 2015Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes InsipidusDiabetes Insipidus, NephrogenicDrug: chlorothiazideNational Center for Research Resources (NCRR)Northwestern UniversityNot recruiting6 Months70 YearsBothN/A

先頭へ